Previous 10 | Next 10 |
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its t...
2023-10-02 09:33:00 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Call Transcript Syros falls as Pfizer ends collaboration Seeking Alpha’s...
-- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tami...
2023-08-16 10:08:58 ET Gainers: Novo Integrated Sciences ( NVOS ) +86% . Aeon Biopharma ( AEON ) +11% . Biophytis ( BPTS ) +10% . Syros Pharmaceuticals ( SYRS ) +9% . MediciNova ( MNOV ) +8% . Losers: Impel Pharmaceuticals...
2023-08-08 11:12:07 ET Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Conference Call August 08, 2023 08:30 AM ET Company Participants Karen Hunady - Director, IR and Corporate Communications Nancy Simonian - President and CEO David Roth - CMO Jason Haas...
2023-08-08 07:37:47 ET Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q2 GAAP EPS of $1.30 beats by $2.43 . Revenue of $2.8M (-55.4% Y/Y) misses by $0.7M . Cash, cash equivalents and marketable securities as of June 30, 2023 were $144 million, as compare...
-- On track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 -- -- Expect to complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023; pivotal CR data expected in 3Q 2024 -- -- Management to host a conference call at 8:30 a.m. ET today -- ...
2023-08-07 12:46:32 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$1.13 and the consensus Revenue Estimate is $3.5M (-44.3% Y/Y). Over the last 2 years, ...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its seco...
2023-07-21 17:17:13 ET Gainers: Gritstone bio ( GRTS ) +4.8% . LexinFintech Holdings ( LX ) +4.3% . AppLovin ( APP ) +2.9% . Latham Group ( SWIM ) +2.6% . Accuray ( ARAY ) +2.5% . Losers: ALX Oncology Holdings ( ALXO ...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...